The pharmacokinetics of dexmedetomidine in patients with different levels of obesity

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-15006568

Enrollment

Unknown

Registered

2015-06-14

Start date

2015-05-21

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

morbidly obese

Interventions

A:dexmedetomidine

B:dexmedetomidine

M:dexmedetomidine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Weight: BMI from 28 to 40, 40 to 50 and 18.5 to 24; 2. Written informed consent from the patient or the relatives of the participating patient.

Exclusion criteria

Exclusion criteria: 1. A previous history of intolerance to the study drug or related compounds and additives; 2. Existing significant haematological, endocrine, metabolic or gastrointestinal disease.

Design outcomes

Primary

Measure	Time frame
pharmacokinetics;	—

Countries

China

Contacts

Public ContactBo Xu

xubo333@hotmail.com+86 13802738125

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026